The results of a two-year Phase III study in 3040 patients with rimonabant (Acomplia(TM)), the first in a new class of therapeutic agents called selective CB1 Blockers, demonstrate that the benefits achieved with rimonabant 20mg at the end of the …
ACOMPLIA PRODUCT INFORMATION
The active substance is rimonabant. Each film-coated tablet of Acomplia contains 20mg of rimonabant. The other ingredients are: Tablet Core: maize starch, lactose monohydrate, povidone K30 (E1201), …
Sanofi-Synthelabo, a French Pharmaceutical Company created Rimonabant (Acomplia® and possibly Zimulti) which is a new drug treatment for obesity and possibly other ailments. This diet pill was officially approved in Britain on June 28th 2006. It has also be …